Free Trial
NASDAQ:DRUG

Bright Minds Biosciences Q3 2024 Earnings Report

Bright Minds Biosciences logo
$50.10 -1.01 (-1.98%)
Closing price 09/23/2025 04:00 PM Eastern
Extended Trading
$50.50 +0.40 (+0.80%)
As of 04:18 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bright Minds Biosciences EPS Results

Actual EPS
$0.04
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bright Minds Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bright Minds Biosciences Announcement Details

Quarter
Q3 2024
Time
N/A
Conference Call Date
Wednesday, August 14, 2024
Conference Call Time
4:00PM ET

Earnings Documents

Bright Minds Biosciences Earnings Headlines

Bright Minds Biosciences (NASDAQ:DRUG) Upgraded to Hold at Wall Street Zen
China’s message to Trump
Did China just fire shots at America? Last week, in Tiananmen Square, China put on a chilling display of military power. Fighter jets, tanks, AI-guided drones — all paraded under the red flag, in front of Vladimir Putin, Kim Jong Un, and more than two dozen world leaders.tc pixel
See More Bright Minds Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bright Minds Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bright Minds Biosciences and other key companies, straight to your email.

About Bright Minds Biosciences

Bright Minds Biosciences (NASDAQ:DRUG), trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.

The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders. Its second program, BMB-103, is in preclinical development targeting neuroinflammation and neuronal survival pathways relevant to Alzheimer’s disease. Bright Minds Biosciences operates research facilities in Vancouver and Montreal, collaborating with academic institutions and industry partners to advance its pipeline through both early-stage and later-stage clinical studies.

Founded in 2020, Bright Minds completed its initial public listing to support ongoing research and development activities. The company’s leadership team includes experienced researchers, medicinal chemists and clinical development experts committed to translating cutting-edge neuroscience into scalable therapies. By focusing on small-molecule alternatives to traditional biologics, Bright Minds Biosciences seeks to offer patients oral treatments with favorable safety profiles and broad commercial applicability.

View Bright Minds Biosciences Profile

More Earnings Resources from MarketBeat